Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Liraglutide Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the liraglutide market has seen a robust growth. Projections indicate an increase in market size from $6.38 billion in 2024 to $6.95 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%. The growth witnessed in the historic period is largely due to the surge in type 2 diabetes diagnoses, escalating obesity levels, widespread clinical trials, enhanced understanding of diabetes-related complications, and innovative advancements in drug delivery systems.

What Is the Forecast for the Liraglutide Market Size Through 2029?

In the coming years, robust growth is anticipated in the liraglutide market. The market is predicted to expand to $9.66 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This projected growth can be linked to a rise in insurance and reimbursement policies, development in healthcare infrastructure, increased awareness and educational initiatives, an aging population, and the escalating incidence of diabetes. Dominant trends for the forecast period include artificial intelligence and machine learning applications, a heightened demand for wearable technology, the integration of continuous glucose monitoring, advancements in biotechnology, and the emergence of digital health platforms.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

What are the Key Market Players in Liraglutide Market and How They’re Evolving?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

What Are the Primary Growth Drivers in the Liraglutide Market?

The surge in the population suffering from diabetes is predicted to fuel the expansion of the liraglutide market. Diabetes is a persisting ailment in which the body struggles to control blood sugar levels adequately, either due to insufficient insulin production or ineffective usage of insulin. The prevalence of diabetes is on the rise due to factors like inactive lifestyles, unhealthy eating habits, and escalating obesity rates globally. Diabetes medications like liraglutide assist by imitating the function of the hormone GLP-1, which boosts insulin secretion, reduces blood sugar levels, and encourages weight loss, consequently helping in the management of type 2 diabetes. For example, in March 2024, a report by the UK Government, stated that the ratio of people with type 1 diabetes in England who received all 8 care processes at GP practices participating in the NDA rose to 43.8%, a significant increase from 35.2% in the previous year. Thus, the growing diabetic population is augmenting the growth of the liraglutide market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp

What Are the Leading Segments in the Global Liraglutide Industry?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

What Are the Key Market Trends in the Liraglutide Industry?

Leading entities in the liraglutide market are exploring the new product development stream, emphasizing on the creation of products like the generic version of GLP-1. These moves are geared towards broadening patient treatment avenues while satisfying the market’s call for more economically viable options. Generic GLP-1 points to variants of GLP-1 receptor agonists that come into production after the patents for the original branded substances expire, presenting cost-effective substitutes to treat health problems such as type 2 diabetes and obesity. To illustrate, Teva Pharmaceutical Industries Ltd., a notable pharmaceutical firm hailing from Israel, launched the first generic GLP-1, comparable to Victoza, in the US market in June 2024, answering the growing demand for such treatments. In the context of managing blood sugar levels in adults and individuals aged over 10 suffering from type 2 diabetes, as well as in decreasing the danger of cardiovascular incidents in adults having both type 2 diabetes and existing cardiovascular diseases, liraglutide injections are prescribed.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

What Is the Regional Outlook for the Liraglutide Market?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18659

This Report Delivers Insight On:

1. How big is the liraglutide market, and how is it changing globally?

2. Who are the major companies in the liraglutide market, and how are they performing?

3. What are the key opportunities and risks in the liraglutide market right now?

4. Which products or customer segments are growing the most in the liraglutide market?

5. What factors are helping or slowing down the growth of the liraglutide market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model